Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases

Prostate Cancer and Prostatic Diseases volume 16, pages 23–27 (2013)Cite this article

Subjects

Abstract

Background:

Patients with bone metastases secondary to prostate cancer are predisposed to skeletal-related events (SREs), including spinal cord compression, pathological fracture, surgery to bone and radiotherapy to bone. The objective of this study was to document current patterns of healthcare utilization and costs of SREs in patients with prostate cancer and bone metastases.

Methods:

This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial Claims and Encounters database from September 2002 to June 2011. Study subjects included all persons with claims for prostate cancer and for bone metastases, and one or more claims for an SRE. Unique SRE episodes were identified based on a gap of at least 90 days without an SRE claim, and classified by treatment setting (inpatient or outpatient) and SRE type (spinal cord compression, pathological fracture, surgery to bone or radiotherapy).

Results:

Of 3919 patients with prostate cancer and bone metastases, 2090 (53%) had one or more SRE episodes. Among 1237 patients who met all other criteria, there were 1623 SRE episodes over a mean (s.d.) follow-up of 16.1 (12.9) months. The percent of episodes that required inpatient treatment ranged from 14% (radiotherapy) to 82% (surgery to bone). On average, inpatient episodes with surgery to bone (n=36 episodes) were most costly (mean (s.e.) $88 838 ($11 830)/episode), whereas outpatient episodes with surgery to bone (n=8 episodes) were least costly (mean (s.e.) $4749 ($1690)/episode). Of the total SRE costs (mean (s.e.) $20 984 ($951)/episode), 41% were attributable to outpatient radiotherapy (n=1169 episodes), 23% to inpatient radiotherapy (n=184 episodes), and 19% to inpatient treatment of pathological fractures (n=101 episodes).

Conclusions:

In patients with prostate cancer and bone metastases, SREs are associated with high costs and hospitalizations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. American Cancer Society. Detailed guide: prostate cancer what are the key statistics about prostate cancer? Available at http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics. . Accessed 31 January 2012.

  2. Coleman RE . Skeletal complications of malignancy. Cancer 1997; 80 (8 Suppl): 1588–1594.

    Article  CAS  Google Scholar 

  3. Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–593.

    Article  CAS  Google Scholar 

  4. Ohmori K, Matsui H, Yasuda T, Kanamori M, Yudoh K, Seto H et al. Evaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigrams. Jpn J Clin Oncol 1997; 27: 263–267.

    Article  CAS  Google Scholar 

  5. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195–202.

    Article  CAS  Google Scholar 

  6. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813–822.

    Article  CAS  Google Scholar 

  7. Coleman RE . Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165–176.

    Article  CAS  Google Scholar 

  8. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI . Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005–1007.

    Article  Google Scholar 

  9. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–882.

    Article  CAS  Google Scholar 

  10. Barlev A, Song X, Ivanov B, Setty V, Chung K . Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010; 16: 693–702.

    PubMed  Google Scholar 

  11. Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67: 390–396.

    Article  Google Scholar 

  12. Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006; 4: 341–347.

    PubMed  Google Scholar 

  13. Delea TE, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006; 1: 571–576.

    Article  Google Scholar 

  14. Lage MJ, Barber BL, Harrison DJ, Jun S . The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008; 14: 317–322.

    PubMed  Google Scholar 

  15. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS . Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007; 178 (4 Pt 1): 1423–1428.

    Article  Google Scholar 

  16. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA . Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003; 43: 226–232.

    Article  CAS  Google Scholar 

  17. McKiernan JM, Delea TE, Brandman J, Sung J, Raut M, Oster G . Effects of skeletal complications on total medical care costs in patients with bone metastases of solid tumors. American Society of Clinical Oncology 41st Annual Meeting, May 15, 2005 Orlando, FL (Poster). J Clin Oncol 2004 ASCO Annual Meeting Proceedings 2004; 22: 6057.

    Google Scholar 

  18. Hagiwara M, Oglesby A, Chung K, Zilber S, Delea TE . The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. Community Oncol 2011; 8: 508–515.

    Article  Google Scholar 

  19. Hornbrook MC, Hurtado AV, Johnson RE . Health care episodes: definition, measurement and use. Med Care Rev 1985; 42: 163–218.

    Article  CAS  Google Scholar 

  20. Mehta SS, Suzuki S, Glick HA, Schulman KA . Determining an episode of care using claims data. Diabetic foot ulcer. Diabetes Care 1999; 22: 1110–1115.

    Article  CAS  Google Scholar 

  21. Klinkman MS . Episodes of care for abdominal pain in a primary care practice. Arch Fam Med 1996; 5: 279–285.

    Article  CAS  Google Scholar 

  22. Shekelle PG, Markovich M, Louie R . Comparing the costs between provider types of episodes of back pain care. Spine (Phila Pa 1976) 1995; 20: 221–226 ; discussion 227.

    Article  CAS  Google Scholar 

  23. Deyo RA, Cherkin DC, Ciol MA . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613–619.

    Article  CAS  Google Scholar 

  24. Abrahm JL, Banffy MB, Harris MB . Spinal cord compression in patients with advanced metastatic cancer: ‘all I care about is walking and living my life’. JAMA 2008; 299: 937–946.

    Article  CAS  Google Scholar 

  25. Conway R, Graham J, Kidd J, Levack P . What happens to people after malignant cord compression? Survival, function, quality of life, emotional well-being and place of care 1 month after diagnosis. Clin Oncol (R Coll Radiol) 2007; 19: 56–62.

    Article  CAS  Google Scholar 

  26. Loblaw DA, Perry J, Chambers A, Laperriere NJ . Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005; 23: 2028–2037.

    Article  Google Scholar 

  27. Loblaw DA, Laperriere NJ . Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol 1998; 16: 1613–1624.

    Article  CAS  Google Scholar 

  28. Bureau of Labor Statistics. Consumer Price Index. Medical Care, US City Average. Series Id: CUUR0000SAM, CUUS0000SAM. US Department of Labor: Washington, DC, 2008; Available from URL http://www.bls.gov/cpi/home.htm.

  29. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The paper was funded by Amgen.

Author information

Authors and Affiliations

  1. Policy Analysis Inc. (PAI), Brookline, MA, USA

    M Hagiwara & T E Delea

  2. Amgen Global Health Economics, Thousand Oaks, CA, USA

    M W Saville & K Chung

Authors
  1. M Hagiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T E Delea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M W Saville
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Hagiwara.

Ethics declarations

Competing interests

May Hagiwara, PhD and Thomas E Delea, MSIA are employees of Policy Analysis Inc. (PAI) and have received research funding and consulting fees from Amgen and Novartis. Karen Chung, PharmD, MS is an employee of and owns stock options in Amgen. M Wayne Saville, MD was an employee of and owned stock options in Amgen.

Additional information

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hagiwara, M., Delea, T., Saville, M. et al. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 16, 23–27 (2013). https://doi.org/10.1038/pcan.2012.42

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2012.42

Keywords

This article is cited by

Search

Advanced search

Quick links